Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangchun Han

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Molecular Cancer|October 12, 2019
LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinomaYan Xu, Yuan Li, Jiankang Jin, et al.
Molecular Cancer|March 26, 2021
Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinomaYan Xu, Yuan Li, Jiankang Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal CancerFan Li, Yan Xu, Bovey Liu, et al.
Blood|May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucelVicki Plaks, John M Rossi, Justin Chou, et al.
Cancer Research|December 2, 2025
GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic AdenocarcinomaZiheng Chen, I-Lin Ho, Jintan Liu, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Cancers|November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.
Science Translational Medicine|May 10, 2019
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphomaLiang Zhang, Yixin Yao, Shaojun Zhang, et al.
Nature Communications|August 24, 2024
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomicsJiahui Jiang, Yunhe Liu, Jiangjiang Qin, et al.
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Molecular Cancer|October 12, 2019
LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinomaYan Xu, Yuan Li, Jiankang Jin, et al.
Molecular Cancer|March 26, 2021
Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinomaYan Xu, Yuan Li, Jiankang Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal CancerFan Li, Yan Xu, Bovey Liu, et al.
Blood|May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucelVicki Plaks, John M Rossi, Justin Chou, et al.
Cancer Research|December 2, 2025
GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic AdenocarcinomaZiheng Chen, I-Lin Ho, Jintan Liu, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Cancers|November 13, 2021
Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.
Science Translational Medicine|May 10, 2019
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphomaLiang Zhang, Yixin Yao, Shaojun Zhang, et al.
Nature Communications|August 24, 2024
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomicsJiahui Jiang, Yunhe Liu, Jiangjiang Qin, et al.
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
Pageof 6